Evotec SEEvotec's platform and services are being utilized in a new collaboration, generating milestone payments.
Evotec SE and Odyssey Therapeutics have entered a strategic R&D collaboration to discover potential new treatments for autoimmune and inflammatory diseases. Under the agreement, Odyssey will leverage Evotec's integrated data-driven discovery platform, advanced screening capabilities, and AI-enabled data science technologies to discover and validate differentiated small molecule drug candidates across multiple high-value disease targets. The collaboration combines Odyssey's disease biology expertise with Evotec's proprietary compound libraries and discovery infrastructure to accelerate early-stage research. Evotec is eligible to receive milestone payments based on the successful delivery of validated hit series for each target, though detailed financials were not disclosed.
Evotec SEEvotec's platform and services are being utilized in a new collaboration, generating milestone payments.
Odyssey Therapeutics, Inc. Common StockOdyssey gains access to Evotec's discovery platform to advance its pipeline.